A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score

Arthritis and Rheumatism

Volumn 44, Issue 4, 2001, Pages 912-920

  Stone, John H ^a   Hoffman, Gary S ^a   Merkel, Peter A ^a   Min, Yuan I ^b   Uhlfelder, Misty L ^b   Hellmann, David B ^b   Specks, Ulrich ^c   Allen, Nancy B ^c   Davis, John C ^c   Spiera, Robert F ^c   Calabrese, Leonard H ^d   Wigley, Fredrick M ^d   Maiden, Nicola ^d   Valente, Robert M ^e   Niles, John L ^f   Fye, Kenneth H ^g   McCune, Joseph W ^h   St clair, E William ⁱ   Luqmani, Raashid A ^j  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e DUKE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BETH ISRAEL MEDICAL CENTER   (United States)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ HARVARD UNIVERSITY   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ARTICLE; DISEASE ACTIVITY; HUMAN; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; VASCULITIS; WEGENER GRANULOMATOSIS;

HUMANS; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; WEGENER GRANULOMATOSIS;

EID: 0035053927     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5     Document Type: Article

References (25)

1. Validity and reliability of lupus activity measures in the routine clinic setting
2. Measurement of systemic lupus erythematosus activity in clinical research
3. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus
4. Derivation of the SLEDAI: A disease activity index for lupus patients
5. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus
6. The lupus activity criteria count (LACC)
7. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis
8. Validity of a Vasculitis Activity Index for systemic necrotizing vasculitis
9. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group
10. Criteria for disease activity in Wegener's granulomatosis: A requirement for longitudinal clinical studies
11. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis
12. Wegener's granulomatosis: An analysis of 158 patients
13. Antineutrophil cytoplasmic antibodies
14. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate
15. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone
16. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice
17. The validity of pooled outcome measures (indices) in rheumatoid arthritis clinical trials
18. Etanercept combined with conventional treatment in Wegener's granulomatosis
19. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis
20. Vasculitis affecting the kidney: Presentation, histopathology and long-term outcome
21. Microscopic polyarteritis: Presentation, pathology and prognosis
22. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: A prospective study in 342 patients